Want to see ENVB full AI Analyst Report?
Enveric Biosciences (ENVB) Ratios
Enveric Biosciences Ratios
ENVB's free cash flow for Q2 2026 was $-2.44M. For the 2026 fiscal year, ENVB's free cash flow was increased by $0.00 and operating cash flow was $-2.44M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.38 | 1.84 | 1.53 | 4.61 | 8.51 |
| Quick Ratio | 5.38 | 1.84 | 1.53 | 4.61 | 8.51 |
| Cash Ratio | 5.09 | 1.50 | 0.98 | 4.44 | 8.33 |
| Solvency Ratio | -12.99 | -6.20 | 0.17 | -4.52 | -10.94 |
| Operating Cash Flow Ratio | -8.86 | -5.19 | -6.01 | -4.29 | -5.50 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 4.02M | $ 1.24M | $ 1.24M | $ 14.44M | $ 13.32M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.22 | 1.94 | 2.20 | 1.33 | 1.20 |
| Debt Service Coverage Ratio | -112551.96 | 0.00 | -4553.32 | -3435.11 | -4680.59 |
| Interest Coverage Ratio | -82777.81 | 0.00 | -4435.93 | -3802.90 | -2514.98 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.02 | 0.33 | 4.74 |
| Net Debt to EBITDA | 0.55 | 0.24 | 0.14 | 0.90 | 0.31 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 138.30% | 100.09% | 0.10% | 92.72% | 86.79% |
| EBT Per EBIT | 99.97% | 99.31% | 104.95% | 99.98% | 217.51% |
| Return on Assets (ROA) | -238.06% | -310.62% | -0.40% | -94.64% | -183.30% |
| Return on Equity (ROE) | -290.40% | -601.14% | -0.88% | -126.12% | -219.57% |
| Return on Capital Employed (ROCE) | -210.04% | -604.74% | -840.78% | -128.31% | -105.31% |
| Return on Invested Capital (ROIC) | -210.04% | -604.74% | -840.78% | -118.27% | -91.00% |
| Return on Tangible Assets | -238.06% | -314.93% | -0.42% | -96.51% | -268.99% |
| Earnings Yield | -998.45% | -353.90% | -0.04% | -23.46% | -14.87% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.35 | 0.65 | 0.33 | 0.94 | 1.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1055.83 | -564.28 | -1090.25 | -388.55 | -365.95 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1055.83 | 564.28 | 1090.25 | 388.55 | 365.95 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -24.32 | -184.36 | -66.91 | -81.41 | -291.08 |
| Free Cash Flow Per Share | -24.32 | -184.36 | -66.94 | -84.18 | -313.05 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -2720.93 | -29.35 | -13.25 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -2720.93 | -29.35 | -13.25 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | -268.67 | -64.99 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -670.07% | -285.56% | -28.61% | -22.48% | -3.74% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.10 | -0.28 | -2850.40 | -4.26 | -6.73 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.29 | 1.70 | 25.19 | 5.37 | 14.77 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.15 | -0.35 | -3.50 | -4.45 | -26.74 |
| Price-to-Operating Cash Flow Ratio | -0.15 | -0.35 | -3.50 | -4.60 | -28.75 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -0.00 | -267.13 | 0.05 | -0.08 |
| Enterprise Value Multiple | 0.40 | -0.05 | -2.79 | -3.14 | -5.60 |
| Enterprise Value | -3.46M | 464.55K | 47.00M | 61.20M | 312.28M |
| EV to EBITDA | 0.40 | -0.05 | -2.79 | -3.14 | -5.60 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.43 | -0.06 | -3.33 | -3.45 | -25.34 |
| EV to Operating Cash Flow | 0.43 | -0.06 | -3.33 | -3.57 | -27.26 |
| Tangible Book Value Per Share | 12.48 | 37.00 | 8.29 | 72.06 | 350.45 |
| Shareholders’ Equity Per Share | 12.48 | 38.01 | 9.29 | 69.66 | 566.69 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.38 | -0.00 | -0.00 | 0.07 | 0.13 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -36.24 | -228.48 | -0.08 | -87.85 | -1244.27 |
| Tax Burden | 1.38 | 1.00 | 0.00 | 0.93 | 0.87 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.93 | 0.81 | 0.82 | 0.93 | 0.23 |
Currency in USD